885PR on Lymphocide
- Sep 8, 1998Greetings,
For those of you following baseball, did you know this?
"Roger Maris died of lymphoma, a cancer that attacks the body's lymph
system, in 1985. He was 51."
Here is a recent press release on Lymphocide.
Tuesday September 8, 11:44 am Eastern Time
Company Press Release
SOURCE: Immunomedics, Inc.
Advances Reported with Immunomedics' Antibody Products at International
Sixteen Papers Presented on Products at the Joint Congress of the European
Association of Nuclear Medicine and the World Federation of Nuclear
Medicine and Biology in Berlin, Germany
MORRIS PLAINS, N.J., Sept. 8 /PRNewswire/ -- Immunomedics, Inc. (Nasdaq:
IMMU - news) announced today that U.S. and European investigators reported
on progress with the Company's experimental cancer therapeutics and
diagnostic imaging agents in over 16 papers presented at this world
congress held in Berlin last week. The congress was attended by several
thousand nuclear physicians and other specialists from all parts of the world.
CEA-Cide(TM) is being studied by Drs. T. Behr and W. Becker and associates
at the University of Goettingen Hospital, in Germany, in an ongoing
dose-escalation trial in patients with colorectal cancer recurrence or
spread. Among the first 10 patients treated, 2 (20%) have already shown a
partial response (more than 50% tumor regression), although the optimal
dose has not yet been achieved. This is consistent with an earlier study
performed by this German research team, where a 28% objective tumor
response was found in 40 patients treated with another antibody that
appears to be less reactive with carcinoembryonic antigen (CEA) than
CEA-Cide's antibody. Also, the current study uses the humanized version of
the Company's anti-CEA antibody.
Results with the Company's LymphoCide(TM) therapeutic for non-Hodgkin's
lymphoma (NHL) were presented by Dr. J. Tennvall of the University Hospital
in Lund, Sweden, and by Dr. D.M. Goldenberg of the Garden State Cancer
Center and Immunomedics, in New Jersey. In advanced NHL patients, including
those with aggressive forms of this disease, Drs. Tennvall and Goldenberg
reported that LymphoCide induced major and minor responses as well as
stabilization in about one-third of the combined total of 18 patients. Dr.
Goldenberg also reported that the new version of LymphoCide, consisting of
a humanized anti-CD22 antibody labeled with yttrium-90, a powerful
therapeutic radionuclide, has already shown partial responses in 2 of the
first 7 patients studied, all of whom had failed prior chemotherapy and
having some of the prognostically worst forms of NHL.
Cancer and Infectious Disease Imaging
Papers delivered by Dr. V. Ivancevic of the Charite University Hospital in
Berlin and Dr. S. Gratz of the University of Goettingen Hospital, Germany,
reported on the usefulness of LeukoScan(R) in the diagnosis of low-grade
osteomyelitis, especially in patients with prosthetic hip replacement, and
in patients with arthritis, endocarditis, and atypical appendicitis.
At the University of Goettingen, Germany, it was found that Immunomedics'
MyeloScan(TM) product for the detection of cancer spread to the bone
marrow, which is a prevalent finding in patients with lymphoma, myeloma,
breast, prostate, and lung cancers, was successful within 30 to 60 minutes
of being injected. The product consists of the same antibody used in the
Company's LeukoScan infectious disease imaging product, but in a different
formulation so as to allow intense and rapid bone marrow imaging. In a
series of 20 patients studied, it was reported that MyeloScan could reveal
92% of the cancers that were known to have spread to the bone marrow, with
additional, previously unknown lesions found in 5 patients.
Commenting on the success of this congress for the Company, its President
and Chief Executive Officer, Robert J. DeLuccia, stated: ``We are very
gratified with the excellent progress reported on our technologies and
products at this international forum. The therapeutic and imaging products
under development are moving forward in clinical testing, while the already
commercialized agents, such as LeukoScan in Europe, are finding more
Immunomedics is a biopharmaceutical company focused on the development,
manufacture and commercialization of diagnostic imaging and therapeutic
products for the detection and treatment of cancer and infectious diseases.
Integral to these products are highly specific monoclonal antibodies and
antibody fragments designed to deliver radioisotopes and chemotherapeutic
agents to tumors and sites of infection. The Company's first product,
CEA-Scan(R) for the detection of colorectal cancer, has been approved in
the United States, Canada, and Europe. The Company's second diagnostic
imaging product, LeukoScan(R), has been approved for sale in Europe for the
diagnosis of osteomyelitis (bone infection). This product is presently
under regulatory review by the U.S. Food and Drug Administration.
Immunomedics also has several other diagnostic imaging products and two
therapeutic products in clinical trials.
This release, in addition to historical information, contains certain
forward-looking statements made pursuant to the Private Securities
Litigation Reform Act of 1995. Such statements may involve significant
risks and uncertainties and actual results could differ materially from
those expressed or implied herein. Factors that could cause such
differences include, but are not limited to, new product development
(including clinical trials outcome and regulatory requirement/actions),
competitive risks to marketed products and availability of financing and
other sources of capital as well as those discussed in the Company's Annual
Report on Form 10-K for the year ended June 30, 1997.
SOURCE: Immunomedics, Inc.